Fulgent Genetics, Inc 8-K, filed Jan 12, 2023
Fulgent Genetics, Inc. (FLGT)
About this 8-K
Fulgent Genetics, Inc filed this 8-K on January 12, 2023, reporting on events of January 6, 2023.
Items reported
- Item 1.01: Entered into a material agreement
- Item 9.01: Financial statements and exhibits
!
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of Principal Executive Offices) |
(Zip Code) |
(
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On January 6, 2023, Fulgent Therapeutics LLC, a subsidiary of Fulgent Genetics, Inc. (the “Company”), amended its existing office lease agreement for the Company’s headquarters at 4978 Santa Anita Avenue, Temple City, California 91780 (the “Lease Amendment”). Under the terms of the Lease Amendment, the term of the lease was extended from January 31, 2023 to January 31, 2024 (the “Extended Term”). The Company’s monthly rent payments will be $24,885.00 for the duration of the Extended Term. The Company will also be required to pay for utilities, upkeep and maintenance applicable to the leased premises.
A copy of the Lease Amendment is filed herewith as Exhibit 1.1, and is incorporated by reference as though fully set forth herein. The foregoing description of the agreement is not intended to be complete and is qualified in its entirety by the complete text of the Lease Amendment.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
|
Description |
1.1 |
|
Commercial Lease Addendum (II) by and between Fulgent Therapeutics LLC and E&E Plaza LLC |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 12, 2023 |
FULGENT GENETICS, INC. |
||
|
|
|
|
|
By: |
|
/s/ Paul Kim |
|
Name: |
|
Paul Kim |
|
Title: |
|
Chief Financial Officer |
Exhibit 1.1
COMMERCIAL LEASE ADDENDUM (II)
This LEASE ADDENDUM II to the Commercial Lease Agreement signed on February 1, 2018 by E&E Plaza LLC ("Lessor") and Fulgent Therapeutics LLC ("Lessee"). This document modifies the Commercial Lease Agreement as describe below:
Lessee: Fulgent Therapeutics, LLC |
|
Lessor: E&E Plaza LLC |
By: /s/ Jian Xie |
|
By: /s/ Marlene Xu |
Tittle: COO |
|
Title: MG |
Date: 1/4/2023 |
|
Date: 1/6/2023 |
|
|
|